Premier Research, a global leader in clinical research, product development, and consulting, has joined forces with BioCentriq, a Contract Development and Manufacturing Organization (CDMO), in a strategic partnership aimed at transforming the pre-Investigational New Drug (IND) process and expediting the clinical translation of innovative cell therapy products.
By combining Premier Research's extensive expertise in cell therapy product development with BioCentriq's proficiency in the development, manufacturing, and testing of cell therapies, this partnership seeks to streamline the pathway for introducing new products to patients. Premier and BioCentriq, as collaborative partners, are poised to assist sponsors in hastening the transition of their groundbreaking cell therapy candidates from research to clinical trials.
This collaboration capitalizes on Premier Research's in-depth knowledge of regulatory requirements, clinical trial design, and study execution, complemented by BioCentriq's specialized capabilities in the development of cell therapies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!